Spero Therapeutics (SPRO) Receivables - Other (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Receivables - Other came in at $44000.0 in Q1 2026, up 101.82% YoY from $21801.6 in Q1 2025, and up 102.82% on a QoQ basis from -$1.6 million in Q4 2025.
Spero Therapeutics (SPRO) Receivables - Other (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Receivables - Other data on file, last reported at $44000.0 in Q1 2026.
- Quarterly Receivables - Other rose 101.82% year-over-year to $44000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44000.0 (up 101.32% YoY) and the FY2025 annual result came in at -$3.1 million, down 199.09% from the prior year.
- Receivables - Other rose to $44000.0 in Q1 2026, from -$1.6 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $5.0 million in Q1 2024 to a low of -$2.4 million in Q1 2025.
- A 5-year average of $1.3 million and a median of $1.6 million in 2025 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2022 — Receivables - Other soared 244.74% — and 2023, when it tumbled 1202.29%.
- Tracing SPRO's Receivables - Other over 5 years: stood at $131000.0 in 2022, then plunged by 1202.29% to -$1.4 million in 2023, then surged by 126.94% to $389000.0 in 2024, then slumped by 501.8% to -$1.6 million in 2025, then surged by 102.82% to $44000.0 in 2026.
- The last three Receivables - Other figures came in at $44000.0 (Q1 2026), -$1.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19,000.00 |
| Jun 30, 2026 | -19,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | -1.56 Mn |
| Dec 31, 2025 | -1.56 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 2.46 Mn |
| Mar 31, 2025 | -2.42 Mn |
| Mar 31, 2025 | -2.42 Mn |
| Dec 31, 2024 | 389,000.00 |
| Dec 31, 2024 | 389,000.00 |
| Sep 30, 2024 | 2.70 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Mar 31, 2024 | 5.02 Mn |
| Mar 31, 2024 | 5.02 Mn |